Protalix Biotherapeutics
Yahoo Finance • 12 months ago
Levicept Appoints Eliot Forster as CEO
Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology compan... Full story
Yahoo Finance • 2 years ago
Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases
Milestone payment triggered by FDA approval of ELFABRIO® (pegunigalsidase alfa-iwxj) and payable within 30 days of approval CARMIEL, Israel, May 18, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceut... Full story
Yahoo Finance • 2 years ago
Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, May 4, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and co... Full story
Yahoo Finance • 2 years ago
Protalix BioTherapeutics Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe Gout
PRX-115 is a PEGylated recombinant uricase produced from the proprietary ProCellEx® platform as a potential treatment of severe gout CARMIEL, Israel, March 21, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE... Full story
Yahoo Finance • 2 years ago
Protalix BioTherapeutics to Report Third Quarter 2022 Financial and Business Results on November 14, 2022
Company to host conference call and webcast at 8:30 a.m. EST CARMIEL, Israel, Nov. 7, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production... Full story
Yahoo Finance • 3 years ago
Protalix BioTherapeutics Reports Fiscal Year 2021 Financial and Business Results
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, March 31, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, producti... Full story
